Ivabradine Krka

Active Ingredient:: Ivabradine
Origin:: EU

Ivabradine Krka (Ivabradine)

Q: What is Ivabradine Krka used for?

Ivabradine Krka is prescribed to lower heart rate in adults with chronic stable angina and in patients with heart failure with reduced ejection fraction. By reducing the heart rate, it helps relieve angina symptoms and may improve functional capacity in heart‑failure patients when used alongside standard therapy.

Q: How does ivabradine work?

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, which is responsible for spontaneous pacemaker activity. Inhibition of this current slows the rate of depolarization, leading to a lower resting heart rate without affecting myocardial contractility or systemic blood pressure.

Q: What is the usual dose of ivabradine?

The specific dose of ivabradine is determined by the prescribing clinician based on the patient’s clinical condition, baseline heart rate, and tolerance. Dosage adjustments may be required for hepatic impairment or when interacting medications are present, and the prescriber will follow the approved labeling guidelines.

Q: Is ivabradine safe in pregnancy or breastfeeding?

The safety of ivabradine during pregnancy and lactation has not been established, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus, and breastfeeding mothers should consult their healthcare provider before use.

Q: How do I order Ivabradine Krka from GNH India?

To place an order, submit an enquiry on the Ivabradine Krka product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Q: How does ivabradine compare with beta‑blockers?

Both ivabradine and beta‑blockers lower heart rate, but they act via different mechanisms. Beta‑blockers reduce heart rate by blocking adrenergic receptors and also lower blood pressure, whereas ivabradine selectively inhibits the If current without affecting contractility or blood pressure. Ivabradine is often considered when beta‑blockers are contraindicated or insufficient for heart‑rate control.

Q: How should Ivabradine Krka be stored and handled?

Ivabradine Krka tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in the bathroom or near heat sources.

Q: How is Ivabradine Krka administered?

Ivabradine Krka is taken orally, usually with a glass of water. It is typically administered twice daily, with the first dose taken in the morning and the second dose taken at least 12 hours after the first. The exact timing and dosing schedule should be prescribed by a qualified healthcare professional.

Q: What are the most serious risks to watch for with ivabradine?

The most serious risks include severe bradycardia (resting heart rate below 40 bpm), symptomatic atrial fibrillation, and significant hypotension that may lead to syncope. Patients should be instructed to report any episodes of dizziness, fainting, or palpitations promptly, and regular monitoring of heart rate is recommended.

Q: Who should not use ivabradine?

Ivabradine should be avoided in patients with a resting heart rate below 50 bpm, those with acute decompensated heart failure, severe hepatic impairment, or known hypersensitivity to the drug. It is also contraindicated when used together with strong CYP3A4 inhibitors without appropriate dose adjustment.

Ivabradine, the active ingredient in Ivabradine Krka, is an If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate by selectively inhibiting the funny current in the sinoatrial node and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH India supplies Ivabradine Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ivabradine acts on the cardiac conduction system by selectively inhibiting the If current, and is used in specific cardiovascular conditions.

Chronic stable angina: reduces frequency of angina attacks and improves exercise tolerance.
Heart failure with reduced ejection fraction: lowers heart rate and may improve clinical outcomes in NYHA class II–III patients.
Symptomatic coronary artery disease despite optimal therapy: provides additional heart‑rate control when beta‑blockers are insufficient.

How It Works

Ivabradine selectively binds to the hyperpolarization‑activated cyclic nucleotide‑gated (HCN) channels that generate the funny (If) current in the sinoatrial node. By inhibiting this inward sodium/potassium current, the drug slows spontaneous depolarization, leading to a reduction in resting heart rate without affecting myocardial contractility or blood pressure.

Side Effects

Common Side Effects

Bradycardia: resting heart rate may fall below 50 bpm.
Luminous phenomena (phosphenes): transient visual sensations, especially in low light.
Headache: mild to moderate intensity.
Dizziness or fatigue: often related to reduced heart rate.

Serious or Rare Side Effects

Severe bradycardia requiring medical intervention.
Atrial fibrillation or other significant arrhythmias.
Symptomatic hypotension or syncope.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate cardiac status and concomitant medications.

Assess baseline heart rate: ensure resting HR ≥ 50 bpm before starting.
Monitor for symptomatic bradycardia: discontinue if HR < 40 bpm or if patient experiences dizziness.
Avoid use in acute decompensated heart failure or unstable angina.
Caution in hepatic impairment: dose adjustment may be required.
Avoid concomitant strong CYP3A4 inhibitors without dose modification.
Store at ambient temperature: keep in original container, protect from moisture and light.

Avoid Interactions

Ivabradine may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase ivabradine plasma levels.
Co‑administration with other heart‑rate‑lowering agents (beta‑blockers, digoxin): risk of excessive bradycardia.
Sotalol: combined use may precipitate severe bradycardia.

Moderate Interactions (Monitor Closely)

Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may require dose reduction.
CYP3A4 inducers (e.g., rifampicin, carbamazepine): can reduce ivabradine efficacy.
Certain antidepressants affecting CYP3A4 (e.g., sertraline): monitor heart rate and adjust if needed.

Frequently Asked Questions

Ivabradine Krka is prescribed to lower heart rate in adults with chronic stable angina and in patients with heart failure with reduced ejection fraction. By reducing the heart rate, it helps relieve angina symptoms and may improve functional capacity in heart‑failure patients when used alongside standard therapy.

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, which is responsible for spontaneous pacemaker activity. Inhibition of this current slows the rate of depolarization, leading to a lower resting heart rate without affecting myocardial contractility or systemic blood pressure.

The specific dose of ivabradine is determined by the prescribing clinician based on the patient’s clinical condition, baseline heart rate, and tolerance. Dosage adjustments may be required for hepatic impairment or when interacting medications are present, and the prescriber will follow the approved labeling guidelines.

The safety of ivabradine during pregnancy and lactation has not been established, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus, and breastfeeding mothers should consult their healthcare provider before use.

To place an order, submit an enquiry on the Ivabradine Krka product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but they act via different mechanisms. Beta‑blockers reduce heart rate by blocking adrenergic receptors and also lower blood pressure, whereas ivabradine selectively inhibits the If current without affecting contractility or blood pressure. Ivabradine is often considered when beta‑blockers are contraindicated or insufficient for heart‑rate control.

Ivabradine Krka tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in the bathroom or near heat sources.

Ivabradine Krka is taken orally, usually with a glass of water. It is typically administered twice daily, with the first dose taken in the morning and the second dose taken at least 12 hours after the first. The exact timing and dosing schedule should be prescribed by a qualified healthcare professional.

The most serious risks include severe bradycardia (resting heart rate below 40 bpm), symptomatic atrial fibrillation, and significant hypotension that may lead to syncope. Patients should be instructed to report any episodes of dizziness, fainting, or palpitations promptly, and regular monitoring of heart rate is recommended.

Ivabradine should be avoided in patients with a resting heart rate below 50 bpm, those with acute decompensated heart failure, severe hepatic impairment, or known hypersensitivity to the drug. It is also contraindicated when used together with strong CYP3A4 inhibitors without appropriate dose adjustment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 14 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.